Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.35 USD | +3.21% | -1.42% | +52.37% |
Apr. 18 | ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing | MT |
Apr. 18 | ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing | MT |
Chart calendar ARS Pharmaceuticals, Inc.
Upcoming events on ARS Pharmaceuticals, Inc.
Past events on ARS Pharmaceuticals, Inc.
2024-03-21 04:05 pm | Q4 2023 Earnings Release |
2024-03-13 10:00 am | Leerink Partners Global Biopharma Conference - Fireside Chat |
2024-03-07 01:00 pm | Investor Day |
2024-02-26 12:45 pm | American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 788 |
2024-02-24 09:45 am | American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 240 |
2024-02-24 09:45 am | American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: L32 |
2024-02-24 09:45 am | American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 299 |
2024-02-23 03:15 pm | American Academy of Allergy, Asthma & Immunology Meeting - Poster Number: 033 |
2023-11-12 02:35 pm | American College of Allergy Asthma and Immunolog Scientific Meeting |
2023-11-11 07:30 pm | American College of Allergy Asthma and Immunolog Scientific Meeting |
2023-11-10 08:45 pm | American College of Allergy Asthma and Immunolog Scientific Meeting |
2023-11-10 07:30 pm | American College of Allergy Asthma and Immunolog Scientific Meeting |
2023-11-09 04:00 pm | Q3 2023 Earnings Release |
2023-08-10 04:00 pm | Q2 2023 Earnings Release |
2023-06-27 12:00 pm | Annual General Meeting |
2023-05-15 09:00 am | Q1 2023 Earnings Release |
2023-03-23 04:01 pm | Q4 2022 Earnings Release |
2023-02-24 03:15 pm | American Academy of Allergy, Asthma & Immunology Meeting - Results of a Patient/Caregiver Survey |
2023-02-24 03:15 pm | American Academy of Allergy, Asthma & Immunology Meeting - Epinephrine Auto-Injector-Prescriptions N |
2023-02-24 03:15 pm | American Academy of Allergy, Asthma & Immunology Meeting - 1.0 mg and 2.0 mg Doses |
Annual results
Fiscal Period | December | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 1,32 1,27 3.89% | 0,03 0,01 200% | 5,54 |
EBITDA | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | 0,00 | -35,5 -76,8 53.78% | -67,5 -76,2 11.36% | -64,9 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -34,7 -74,8 53.65% | -54,4 -63,6 14.53% | -55,4 |
Net income Million USD | Released Forecast Spread | -20,2 | -34,7 -73,2 52.63% | -54,4 -60,8 10.58% | -59,2 |
EPS USD | Released Forecast Spread | -0,83 | -0,87 -1,33 34.34% | -0,57 -0,64 10.94% | -0,61 |
Announcement Date | 06/10/22 | 23/03/23 | 21/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,10 - | 0,02 0,00 - | 0,01 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 1,00 | 4,34 | 2,80 |
EBIT Million USD | Released Forecast Spread | -15,4 -12,1 -27.38% | -18,7 -18,0 -4.08% | -20,6 -20,3 -1.25% | -18,0 -21,0 14.34% | -57,3 -17,5 -228.25% | -10,2 | -11,1 | -18,8 | -24,7 | |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,4 -12,9 -11.78% | -15,0 -17,6 14.88% | -17,4 -18,4 5.63% | -14,9 -18,8 20.71% | -7,17 -15,0 52.25% | -7,49 | -8,48 | -16,7 | -22,7 | |
Net income Million USD | Released Forecast Spread | -14,4 -12,9 -11.78% | -15,0 -15,8 5.01% | -17,4 -16,4 -6.1% | -14,9 -17,5 15.21% | -7,17 -13,6 47.33% | -10,4 | -12,5 | -16,2 | -20,1 | |
EPS USD | Released Forecast Spread | -0,09 -0,14 35.71% | -0,16 -0,17 4% | -0,18 -0,17 -3.85% | -0,16 -0,18 12.73% | -0,07 -0,14 50% | -0,11 | -0,13 | -0,17 | -0,21 | -0,19 |
Announcement Date | 23/03/23 | 15/05/23 | 10/08/23 | 09/11/23 | 21/03/24 | - | - | - | - | - |
Today 04:05 pm | QIAGEN N.V.: Q1 2024 Earnings Release |
2024-04-29 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
2024-04-30 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
2024-04-30 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
2024-04-30 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
2024-04-30 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
2024-05-01 06:30 am | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
2024-05-01 06:30 am | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
2024-05-01 07:00 am | ALKERMES PLC: Q1 2024 Earnings Release |
2024-05-01 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for ARS Pharmaceuticals, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- SPRY Stock
- Calendar ARS Pharmaceuticals, Inc.